EANS-Adhoc: Intercell AG provides update on IXIARO®/JESPECT® sales growth and expected full year financial performance
16.10.2012 – 07:32
-------------------------------------------------------------------------------- ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. -------------------------------------------------------------------------------- Company Information 16.10.2012 » Preliminary, unaudited third quarter close shows approximately EUR 18m IXIARO®/JESPECT® sales for the nine months ended September 30th 2012 - representing significant growth compared to EUR 15.5m sales in the same period of 2011 » However, previous sales growth expectations had been higher and full year sales and net loss expectations are therefore lowered by 10% to 20% Vienna, October 16, 2012 - Intercell AG (VSE: ICLL) today announced an adjustment of its product sales expectations for IXIARO®/JESPECT®, a vaccine to prevent Japanese Encephalitis, and expected full year net loss ahead of its Q3 2012 financial results announcement, scheduled for November 7th, 2012. Following an analysis of recent vaccine adoption trends and the expected order intake for the rest of the year, Intercell now expects 2012 IXIARO®/JESPECT® sales growth of EUR 5m to 7m, resulting in expected product sales between EUR 26.5m and 28.5m for the full year 2012 (2011: EUR 21.6m). The company also updated the range of its expected full year net loss to EUR 20m to 24m. For the nine months ended September 30th, 2012, Intercell expects to report a net loss of approximately EUR 14.5m to 15m. Based on the expected orders and demand, and subject to timely product release to secure supply of the vaccine, the revised full year product sales expectation assumes strong Q4 sales of EUR 8.5m to 10.5m (Q4 2011: EUR 6.1m) underscoring the unlocked potential of this vaccine. Further inquiry note: Intercell AG Nina Waibel Corporate Communications Tel. +43 1 20620-1222 communications@intercell.com end of announcement euro adhoc -------------------------------------------------------------------------------- issuer: Intercell AG Campus Vienna Biocenter 3 A-1030 Wien phone: +43 1 20620-0 FAX: +43 1 20620-800 mail: investors@intercell.com WWW: www.intercell.com sector: Biotechnology ISIN: AT0000612601 indexes: ATX Prime stockmarkets: official market: Wien language: English